http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Coniagas Announces Amended and Restated LIFE Offering Document
-
Cogent Biosciences reports positive APEX trial results for bezuclastinib
-
Arrowhead Pharmaceuticals starts phase 1/2a trial for Alzheimer's drug
-
Arrowhead Pharmaceuticals begins Phase 1/2a trial of ARO-MAPT for Alzheimer's
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
-
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
AUDIT BEE WINS DUAL HONOURS AT GLOBAL BRAND AWARDS 2025
-
REKT Announces Launch of the First Meme Token That Rewards Losing Trades
-
X-energy Appoints Daniel Gross as Chief Financial Officer
-
Carolina Rush-OceanaGold Partnership to Commence Deep Drilling at Brewer in January 2026
-
AstroX Finance Debuts Livestream-Powered Multichain Platform, Establishing a New Standard for Creator-Led Token Economies
-
Greenwich LifeSciences completes enrollment in open label arm of phase III trial
-
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
-
Immutable and GAMEDIA's Spider Tanks: Cores of Chaos is Now LIVE to Play Cross-Platform
-
Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober
-
Kohenoor Technologies Announces Launch of ICO Round-2 on December 12, 2025
-
HTX Opens Trading for STABLE (Stable)
-
Apex Completes 2025 Re-Logging and Re-Sampling Program of Preserved Historical Drill Core at The Rift Rare Earth Project, Elk Creek, Nebraska
-
Cogent Biosciences presents full SUMMIT trial results for bezuclastinib
-
Legend Biotech reports 50-month survival data for CARVYKTI in myeloma
-
Kite reports 96% response rate in multiple myeloma trial
-
PureTech gets FDA feedback supporting phase 3 trial for lung drug
-
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
-
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
-
ADAM S. KUTNER, INJURY ATTORNEYS, CELEBRATES FOUR PRESTIGIOUS 2025 BEST OF LAS VEGAS GOLD AWARDS
-
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
-
Christina Galbraith Global Decor Launches a Platform for Interior Design from Underrepresented Geographies
-
Fulcrum reports positive 20 mg dose results for sickle cell drug
-
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual M
-
Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness
-
Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness
-
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
-
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
-
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematolog
-
Nevada Sunrise Clarifies Investor Relations Agreement
-
Aurania raises C$771,777 in private placement financing
-
Aurania Closes Private Placement Financing
-
Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement
-
Edimakor V4.5.0 Unveils NanoBanana Pro & Multiple Avatars Dialogue for Digital Interactions
-
Comprehensive Logistics Honors 30 Years of Ingenuity, Innovation and the People Behind It
-
South Coast AQMD Approves $220K to Extend Coachella Valley Street Sweeping Program
-
Gallop Oncology reports positive Phase 1b trial results for LYT-200
-
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
-
Ringling Bros. and Barnum & Bailey® Collaborates with Country Teen Sensation Maddox Batson on the First-Ever Music Artist Integration in the Brand's 150 Year History with an Exclusive In-Show Rem
-
Dreame Technology Recognized on Fast Company's List of Brands That Matter
-
Edimakor V4.5.0 Unveils NanoBanana Pro and Multiple Avatars Dialogue for Digital Interactions
-
8 Years of CoinEx Voyages: From Exploration to Expansion, Toward Excellence
-
Canadian Gold Corp. Announces Shareholders Approve Arrangement with McEwen
-
AAOS Establishes Orthobiologics Registry to Advance Evidence-Based Orthobiologics Research
-
RCI Banque discloses updated binding MREL requirement

